HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Priorities For Food Safety, Cannabinoid Clear Even With Next Commissioner Unknown

Executive Summary

FDA commissioner should be announced by mid-November and will likely continue to prioritize food and supplement safety, propelled by contaminants found in baby food, say two attorneys with Alston & Bird. A regulatory pathway for cannabidiol also is expected to be a priority once a commissioner is named.

You may also be interested in...



House Appropriators Go Low On FDA's Budget

Appropriation set for CFSAN and ORA’s related field activities is $1.16bn, up slightly from the FY2021 level of $1.1bn, and for CDER and ORA’s related activities is $2.1bn, up $100m from current funding.

Like Sands Through The Hourglass, So Are Janet Woodcock’s Days As Acting FDA Commissioner

Janet Woodcock has been a no-nonsense acting commissioner, but there’s plenty of drama in the nomination process as opposition and support for her to become permanent head of the US FDA continues to mount while the wait for President Biden’s nominee drags on.

US Fertility Supplement Marketers Don’t Deliver

FDA and FTC jointly warn five marketers of supplements with claims to treat fertility and other reproductive disorders. The unapproved and misbranded drugs could harm consumers and deter them from seeking effective treatments.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel